Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: Myeloablative, non-myeloablative, and beyond

References

• Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–7.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexmethasone (Hyper-CVAD), a dose-intenseve regimen, in adult acute lymphoblastic leukemia. Cancer. 2004;101:2788–801.
   PubMed Web of Science ®Google Scholar
• Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104:3028–37.
   PubMed Web of Science ®Google Scholar
• Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009;144:468–83.
   PubMed Web of Science ®Google Scholar
• Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863–71.
   PubMed Web of Science ®Google Scholar
• Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2464–71.
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–73.
   PubMed Web of Science ®Google Scholar
• Chao NJ, Forman SJ, Schmidt GM, Snyder DS, Amylon MD, Konrad PN, et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood. 1991;78:1923–7.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL trial (MRC UKALLXII/ECOG E2993). Blood. 2008;111:1827–33.
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Horowitz MM, Ash RC, Atkinson K, Gale RP, Goldman JM, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992;79:3067–70.
   PubMed Web of Science ®Google Scholar
• Avivi I, Goldstone AH. Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant. 2003;31:623–32.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer. 2011;117:1583–94.
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2005;19:159–16.
   PubMed Web of Science ®Google Scholar
• Fiere D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol. 1993;11:1990–2001.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–86.
   PubMed Web of Science ®Google Scholar
• Oh H, Gale RP, Zhang MJ, Passweg JR, Ino T, Murakami H, et al. Chemotherapy as HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant. 1998;22:253–7.
   PubMed Web of Science ®Google Scholar
• Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <50 years old in first complete remission: results of the EORTC ALL-3 trial. Hematologica. 2004;89:809–17.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Bethencourt C, Parody R, Hernandez-Rivas JM, Moreno MJ, et al. Comparison of intensive chemotherapy, allogenenic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Hematologica. 2005;90:1346–56.
   PubMed Web of Science ®Google Scholar
• Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113(13):3110–8.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001;97:1572–7.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002;8:213–20.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Tang W, Dou HB, Shan JH, Hu J. The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission. Int J Hematol. 2013;98(5):569–77.
   PubMed Web of Science ®Google Scholar
• Marks DI, Perez WS, He W, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008;112(2):426–34.
   PubMed Web of Science ®Google Scholar
• Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in relation compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816–25.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, et al. Allogeneic stem cell transplant for adult Philadelphia chromosome negative acute lymphoblastic leukemia: comparable survival rate but different risk factors between related and unrelated transplant in first complete remission. Blood. 2010;116:4368–75.
   PubMed Web of Science ®Google Scholar
• Chim CS, Lie AKW, Liang R, Au WY, Kwong YL. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor. Bone Marrow Transplant. 2007;40:339–47.
   PubMed Web of Science ®Google Scholar
• Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(9):1083–94.
   PubMed Web of Science ®Google Scholar
• Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009;27(22):3634–41.
   PubMed Web of Science ®Google Scholar
• Dahlke J, Kroger N, Zabelina T, Ayuk F, Fehse N, Wolschke C, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006;37:155–63.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:303–6.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–43.
   PubMed Web of Science ®Google Scholar
• Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia. 2009;23(10):1763–70.
   PubMed Web of Science ®Google Scholar
• Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96(8):1113–20.
   PubMed Web of Science ®Google Scholar
• Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366–74.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113(13):2902–5.
   PubMed Web of Science ®Google Scholar
• Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2009;15(11):1407–14.
   PubMed Web of Science ®Google Scholar
• Busca A, Locatelli F, Flonta SE, Ciccone G, Baldi I, D'Ardia S, et al. In vivo T-cell depletion with pretransplant low-dose antithymocyte globulin is associated with reduced transplant-related mortality and improved clinical outcome in patients receiving allogeneic hematopoietic stem cell transplantation from unrelated and partially matched related donors. Am J Hematol. 2010:214–7.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942–7.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;5:560–5.
   Web of Science ®Google Scholar
• Mohty M, Labopin M, Balère ML, Socié G, Milpied N, Tabrizi R, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia. 2010;24(11):1867–74.
   PubMed Web of Science ®Google Scholar
• Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplant. 2011; 46(8):1102–12.
   PubMed Web of Science ®Google Scholar
• Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, et al. Features of Epstein-Barr virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplant. Leukemia. 2011;6:932–8.
   Google Scholar
• Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica. 2009;94:1399–406.
   PubMed Web of Science ®Google Scholar
• Kanda J, Lopez RD, Rizzieri DA. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93:586–93.
   PubMed Web of Science ®Google Scholar
• Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, et al. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47(4):581–8.
   Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–83.
   PubMed Web of Science ®Google Scholar
• Marks DI, Wang T, Perez WS, Antin JH, Copelan E, Gale RP, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010;116:366–74.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.
   PubMed Web of Science ®Google Scholar
• Horowitz MM. High-resolution typing for unrelated donor transplantation: how far do we go? Best Pract Res Clin Haematol. 2009;22(4):537–41.
   PubMed Web of Science ®Google Scholar
• Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116:129–39.
   PubMed Web of Science ®Google Scholar
• Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ, et al. American Thoracic Society Committee on Idiopathic Pneumonia Syndrome. an official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183(9):1262–79.
   PubMed Web of Science ®Google Scholar
• Cooke KR, Yanik G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease?. Bone Marrow Transplant. 2004;34(9):753–65.
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055–61.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host-disease. N Eng J Med. 2007;356:335–47.
   PubMed Web of Science ®Google Scholar
• Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol. 2009;27(20):3398–409.
   PubMed Web of Science ®Google Scholar